Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Max Healthcare & Tata Institute for Genetics and Society Join Forces to Drive Genomics-Led Care in India
The collaboration will focus on key areas including the study of rare genetic disorders, enhancing neonatal care through genomic analysis, and deploying personalised medicine anchored in genetic profiling.
- By Newsdesk
- New Delhi
- Nov 03, 2025
In a significant step for precision medicine in India, Max Healthcare and the Tata Institute for Genetics and Society (TIGS) have signed a Memorandum of Understanding (MoU) to collaborate on advancing genomics-based healthcare. The alliance is built around a shared vision: integrating genomics research with clinical care to elevate patient outcomes.
Under the agreement, the two organisations will establish a joint platform for research, training, and the exchange of knowledge in genetics and clinical science. The aim is to accelerate the translation of genetic insights into everyday healthcare practice.
The collaboration will focus on key areas including the study of rare genetic disorders, enhancing neonatal care through genomic analysis, and deploying personalised medicine anchored in genetic profiling.
According to Dr Sandeep Budhiraja, Group Medical Director at Max Healthcare, the tie-up marks “a meaningful advancement in our mission to bring cutting-edge science to patients. By embedding genomics into our clinical workflows, we can steer toward a more personalised and effective future of care.”
Dr Rakesh Mishra, Director of TIGS, added that the institute’s dedication to applying advanced science for social good finds an ideal partner in this alliance: “This collaboration offers a unique opportunity to apply our genomics expertise to clinical realities and ensure that our research yields concrete benefits for both patients and society.”
A key focus of the partnership will be on haematology and neonatal medicine — exploring genetic causes of blood disorders, cancers, and critical neonatal conditions, thereby enabling earlier risk detection and customised treatment strategies.
This MoU signals a major stride toward scaling up genomic medicine in India, bringing together clinical insight and scientific capability to make personalised healthcare more accessible and impactful.